Summit Therapeutics Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Miami, FL
SMMT chart
What traders are saying about $SMMT
Latest postsSummit Therapeutics Inc. news
- Summit Therapeutics stock rating reaffirmed at Citizens on trial data
Investing.com ·
- Summit Therapeutics (SMMT) Reiterated at Market Outperform by Citizens - 'Weakness a Buying Opportunity'
StreetInsider ·
- Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
marketbeat.com ·
- Ivonescimab Plus Chemotherapy Improves Overall Survival in Advanced Biliary Tract Cancer - Summit Therapeutics
Oncodaily ·
- Jefferies reiterates Buy on Summit Therapeutics stock, $30 target By Investing.com
Investing.com Nigeria ·
- Jefferies on Summit Therapeutics plc (SMMT): 'We continue to like the setup into HARMONi-3'
StreetInsider ·
- UBS Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $33
Moomoo ·
- Stifel on Summit Therapeutics plc (SMMT): 'We think Akeso’s HARMONi-GI1 data strengthen ivo’s differentiation beyond NSCLC'
StreetInsider ·
- What Do the ESMO 2026 Trial Wins Mean for Summit Therapeutics (NASDAQ:SMMT), Amgen (NASDAQ:AMGN) and Johnson & Johnson (NYSE:JNJ)?
Kalkine ·
- Lunit and Summit to evaluate pathology platform for tumour analysis
pharmaceutical-technology.com ·
- Precision Trading with Summit Therapeutics Inc. (SMMT) Risk Zones
Stock Traders Daily ·
- Lunit and Summit Therapeutics Partner to Apply AI in Immuno-Oncology Research
Voice of Healthcare ·
Summit Therapeutics Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | $0 | $0 | $705,000 |
| Net income | -$1.08B | -$221.3M | -$614.9M | -$78.8M |
| Diluted EPS | $-1.44 | $-0.31 | $-0.99 | $-0.41 |
| Total assets (year end) | $751.2M | $435.6M | $202.9M | $664.2M |
| Cash and equivalents (year end) | $225.3M | $104.9M | $71.4M | $348.6M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Summit Therapeutics Inc.
- Ticker
- SMMT (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Miami, FL
- Fiscal year end
- December 31
- SEC CIK
- 1599298
- Former names
- Summit Therapeutics plc, Summit Corp plc
Frequently asked questions
What exchange is Summit Therapeutics Inc. listed on?
Summit Therapeutics Inc. trades on the Nasdaq under the ticker symbol SMMT.
What industry is Summit Therapeutics Inc. in?
Summit Therapeutics Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Summit Therapeutics Inc. headquartered?
Summit Therapeutics Inc.'s business address on file with the SEC is in Miami, FL.
When does Summit Therapeutics Inc.'s fiscal year end?
Summit Therapeutics Inc.'s fiscal year ends on December 31.
How much revenue did Summit Therapeutics Inc. report?
Summit Therapeutics Inc. reported $0 in revenue for calendar year 2024, according to its SEC filings.